Drugs / TMC647055
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02064842 | Feb → Apr 2014 | — | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 1 | NCT01907724 | May → Aug 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01582035 | Apr 2012 → Nov 2013 | hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 1 | NCT01202825 | Apr 2010 → Nov 2011 | hepatitis C virus infection | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01852604 | Mar 2013 → Apr 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01724086 | Oct 2012 → Sep 2014 | chronic hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-03-16 | Medivir | Results New data on Simeprevir presented at the Conference of the Asian Pacific Association for the Study of the Liver medivir.com ↗
In a phase II study up to 95% cure rates were achieved in HCV genotype (GT)1 infected patients treated with a 3-DAA combination of simeprevir, TMC647055/ritonavir and JNJ-56914845. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMC647055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02064842 ↗ |
| Action | Inhibit | “non-nucleoside NS5B inhibitor TMC647055/ritonavir” PMID 28569206 ↗ May 2017 |
| Modality | Small molecule | — CHEMBL2043025 ↗ |
| Route | Oral | “Planned doses will be 100 mg, 250 mg, 600 mg, 1250 mg, 2000 mg, and 3000 mg of TMC647055 or placebo, administered as a single oral administration.” NCT01202825 ↗ |